| Name | Title | Contact Details |
|---|
Holiday Retirement is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Salem, OR. To find more information about Holiday Retirement, please visit www.holidaytouch.com
zuChem is a leading producer of unique sugars for human health and nutrition. zuChem develops proprietary technologies for the manufacture of glycochemicals and carbohydrates for use in the food, specialty and fine chemical markets. The zuChem approach is unique, combining new proprietary technologies with the more traditional synthetic techniques. zuChem researchers have a proven track record in developing and implementing scalable, industrial quality processes.
Deerwalk Incorporated is a revolutionary Population Health Management and Healthcare Analytics Software Company, which offers customers a range of quality products and services to meet their healthcare needs. Deerwalk`s understanding and experience in the Healthcare Analytics industry is unparalleled, offering Big Data and NoSQL products and services to Third Party Administrators, Brokers and Consultants, Employers and Providers, Health Plans, Accountable Care Organizations, Disease / Care Managers, and Health Coaches.
Thibodaux Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Thibodaux Regional Medical Center is based in Thibodaux, LA. You can find more information on Thibodaux Regional Medical Center at www.thibodaux.com
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.